Latest & greatest articles for hydrocortisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydrocortisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydrocortisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydrocortisone

21. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study.

Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. 21427372 2011 03 23 2011 03 24 2016 10 17 1538-3598 305 12 2011 Mar 23 JAMA JAMA Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. 1201-9 10.1001/jama.2011.360 The role of stress-dose hydrocortisone in the management of trauma patients is currently unknown. To test the efficacy of hydrocortisone therapy in trauma patients. Multicenter, randomized (...) , double-blind, placebo-controlled HYPOLYTE (Hydrocortisone Polytraumatise) study. From November 2006 to August 2009, 150 patients with severe trauma were included in 7 intensive care units in France. Patients were randomly assigned to a continuous intravenous infusion of either hydrocortisone (200 mg/d for 5 days, followed by 100 mg on day 6 and 50 mg on day 7) or placebo. The treatment was stopped if patients had an appropriate adrenal response. Hospital-acquired pneumonia within 28 days. Secondary

JAMA2011

22. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review

Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review Doyle LW, Ehrenkranz RA, Halliday HL CRD summary The review concluded that post-natal hydrocortisone had few beneficial or harmful effects (...) when used for prevention and treatment of bronchopulmonary dysplasia in pre-term infants. These conclusions reflected the data presented, but should be interpreted with caution given the limited number of small heterogeneous studies available and weaknesses in the reported review methods. Authors' objectives To assess the effectiveness of post-natal hydrocortisone for the prevention and treatment of bronchopulmonary dysplasia in pre-term infants. Searching MEDLINE and Cochrane Central Register

DARE.2010

23. Hydrocortisone Therapy for Patients with Septic Shock

Hydrocortisone Therapy for Patients with Septic Shock PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2008

24. Hydrocortisone therapy for patients with septic shock.

Hydrocortisone therapy for patients with septic shock. 18184957 2008 01 10 2008 01 15 2015 11 19 1533-4406 358 2 2008 Jan 10 The New England journal of medicine N. Engl. J. Med. Hydrocortisone therapy for patients with septic shock. 111-24 10.1056/NEJMoa071366 Hydrocortisone is widely used in patients with septic shock even though a survival benefit has been reported only in patients who remained hypotensive after fluid and vasopressor resuscitation and whose plasma cortisol levels did not rise (...) appropriately after the administration of corticotropin. In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned 251 patients to receive 50 mg of intravenous hydrocortisone and 248 patients to receive placebo every 6 hours for 5 days; the dose was then tapered during a 6-day period. At 28 days, the primary outcome was death among patients who did not have a response to a corticotropin test. Of the 499 patients in the study, 233 (46.7%) did not have a response to corticotropin

NEJM2008

27. Hydrocortisone infusion may improve survival in patients with severe community-acquired pneumonia

Hydrocortisone infusion may improve survival in patients with severe community-acquired pneumonia Hydrocortisone infusion may improve survival in patients with severe community-acquired pneumonia | Critical Care | Full Text Advertisement Search BioMed Central articles Search Impact Factor 4.950 Main menu Journal club critique Open Access Hydrocortisone infusion may improve survival in patients with severe community-acquired pneumonia Murugan Raghavan and John A Kellum Critical Care 2005 9 :E24 (...) DOI: 10.1186/cc3896 © BioMed Central Ltd 2005 Published: 20 October 2005 Expanded Abstract Citation Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della PR, Giorgio C, Blasi F, Umberger R, Meduri GU: Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242–248 [ ]. Hypothesis Hydrocortisone infusion in severe community-acquired pneumonia (CAP) attenuates systemic inflammation and leads to earlier

Critical Care - EBM Journal Club2005 Full Text: Link to full Text with Trip Pro

28. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock

Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2005

29. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2002

30. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. 12186604 2002 08 20 2002 08 30 2016 10 17 0098-7484 288 7 2002 Aug 21 JAMA JAMA Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. 862-71 Septic shock may be associated with relative adrenal insufficiency. Thus, a replacement therapy of low doses of corticosteroids has been proposed to treat septic shock. To assess (...) whether low doses of corticosteroids improve 28-day survival in patients with septic shock and relative adrenal insufficiency. Placebo-controlled, randomized, double-blind, parallel-group trial performed in 19 intensive care units in France from October 9, 1995, to February 23, 1999. Three hundred adult patients who fulfilled usual criteria for septic shock were enrolled after undergoing a short corticotropin test. Patients were randomly assigned to receive either hydrocortisone (50-mg intravenous

JAMA2002

31. Hydrocortisone

Hydrocortisone Drug Approval Package: Hydrocortisone NDA #040310 FDA Application U.S. Food & Drug Administration Enter Search terms FDA Application - Hydrocortisone Company: Thames Pharmacal Application No.: 040310 Approval Date: 12/29/2000 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 31, 2003 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information in different file formats, see . Language Assistance Available

FDA - Drug Approval Package2000

32. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.

Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1999

33. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial.

Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. 9989716 1999 02 25 1999 02 25 2015 06 16 0140-6736 353 9151 1999 Feb 06 Lancet (London, England) Lancet Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. 455-8 Reports of mild hypocortisolism in chronic fatigue syndrome led us to postulate that low-dose hydrocortisone therapy may be an effective treatment. In a randomised crossover trial, we screened 218 patients with chronic (...) fatigue. 32 patients met our strict criteria for chronic fatigue syndrome without co-morbid psychiatric disorder. The eligible patients received consecutive treatment with low-dose hydrocortisone (5 mg or 10 mg daily) for 1 month and placebo for 1 month; the order of treatment was randomly assigned. Analysis was by intention to treat. None of the patients dropped out. Compared with the baseline self-reported fatigue scores (mean 25.1 points), the score fell by 7.2 points for patients on hydrocortisone

Lancet1999

34. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial.

Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. 9757853 1998 10 08 1998 10 08 2016 10 17 0098-7484 280 12 1998 Sep 23-30 JAMA JAMA Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. 1061-6 Chronic fatigue syndrome (CFS) is associated with a dysregulated hypothalamic-pituitary adrenal axis and hypocortisolemia. To evaluate the efficacy and safety of low-dose oral hydrocortisone as a treatment for CFS (...) . A randomized, placebo-controlled, double-blind therapeutic trial, conducted between 1992 and 1996. A single-center study in a tertiary care research institution. A total of 56 women and 14 men aged 18 to 55 years who met the 1988 Centers for Disease Control and Prevention case criteria for CFS and who withheld concomitant treatment with other medications. Oral hydrocortisone, 13 mg/m2 of body surface area every morning and 3 mg/m2 every afternoon, or placebo, for approximately 12 weeks. A global

JAMA1998

35. Hydrocortisone Valerate Ointment

Hydrocortisone Valerate Ointment Drug Approval Package: Hydrocortisone Valerate NDA# 75-043 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Hydrocortisone Valerate Ointment, USP Company: Taro Pharmaceuticals Inc. Application No.: 75-043 Approval Date: 8/25/1998 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: August 24, 2001 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information

FDA - Drug Approval Package1998

36. Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure.

Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. 2868207 1986 03 12 1986 03 12 2015 06 16 0140-6736 1 8474 1986 Jan 25 Lancet (London, England) Lancet Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. 181-4 52 severely ill asthmatic patients requiring acute admission to hospital entered a double (...) -blind placebo-controlled trial to determine whether intravenous hydrocortisone given in addition to high-dose oral prednisolone and standard bronchodilator therapy accelerated recovery. Patients who had been given parenteral steroids before admission, by comparison with those who had not received such treatment, had been deteriorating for a shorter period before admission, had received more injected or nebulised bronchodilator therapy, and had higher admission peak flows. As judged by peak flow

Lancet1986

37. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.

Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. 6145832 1984 07 30 1984 07 30 2015 06 16 0140-6736 1 8391 1984 Jun 23 Lancet (London, England) Lancet Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. 1369-73 222 patients with disseminated breast cancer have been randomised to receive either a combination (...) of hormone therapies using tamoxifen, aminoglutethimide with hydrocortisone, and danazol (TAD), or tamoxifen alone. The response to the combination was significantly better (43%) than that to tamoxifen alone (31%). Patients who relapsed after response or failed to respond to tamoxifen were subsequently treated with aminoglutethimide and then, if possible, with danazol. Some patients who received TAD were subsequently treated with alternative endocrine therapy, which was usually medroxyprogesterone

Lancet1984

38. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.

A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. 7019703 1981 09 25 1981 09 25 2013 11 21 0028-4793 305 10 1981 Sep 03 The New England journal of medicine N. Engl. J. Med. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. 545-51 We randomized 96 postmenopausal women with metastatic breast carcinoma to receive surgical (...) adrenalectomy or medical therapy with an adrenal inhibitor, aminoglutethimide (AG), plus replacement hydrocortisone. Before randomization, women were stratified according to disease-free interval, site of dominant disease, and estrogen-receptor status. Of 40 evaluable women treated with AG and hydrocortisone, 53 per cent had objective responses, as compared with 45 per cent of 29 women undergoing surgical adrenalectomy (P value not significant). Responses lasted a mean of 17.2 months in the medical group

NEJM1981